Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
Jennifer Kern Sliwa,1 Cynthia A Bossie,1 Dong-Jing Fu,1 Ibrahim Turkoz,2 Larry Alphs11Janssen Scientific Affairs LLC, 2Janssen Research and Development, LLC, Titusville, NJ, USABackground: A post hoc analysis from a multiphase trial with open-label transition and maintenance phases, a double-blind r...
Guardado en:
Autores principales: | Sliwa JK, Bossie CA, Fu D-J, Turkoz I, Alphs L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/66dd7875e7674fe5b5a049c23e8d9364 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs L, et al.
Publicado: (2013) -
Once-monthly paliperidone injection for the treatment of schizophrenia
por: Delia Bishara
Publicado: (2010) -
Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O'Donnell A, et al.
Publicado: (2021) -
Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
por: Li HF, et al.
Publicado: (2015) -
Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury AC, et al.
Publicado: (2021)